Biomarker findings with benralizumab in CRSwNP are limited but in patients with asthma, benralizumab reduced blood eosinophil counts and reduced serum eosinophil-derived neurotoxin and ECP, and increased serum IL-5, eotaxin-1, and eotaxin-2 (89). Here, IL5 is linked to asthma.